Wall Street analysts forecast that Chimerix Inc (NASDAQ:CMRX) will report earnings per share (EPS) of ($0.49) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.43). Chimerix reported earnings per share of ($0.32) in the same quarter last year, which suggests a negative year over year growth rate of 53.1%. The business is expected to issue its next earnings results on Thursday, March 1st.
On average, analysts expect that Chimerix will report full year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.56). For the next financial year, analysts anticipate that the business will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.12) to ($1.50). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Chimerix.
Chimerix (NASDAQ:CMRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.81 million.
Chimerix (NASDAQ:CMRX) traded up $0.03 on Tuesday, hitting $4.93. The stock had a trading volume of 147,450 shares, compared to its average volume of 242,623. The firm has a market capitalization of $232.34, a P/E ratio of -3.45 and a beta of 1.46. Chimerix has a 12 month low of $4.17 and a 12 month high of $6.64.
In related news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.50% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the stock. AXA raised its stake in Chimerix by 284.9% in the second quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after purchasing an additional 191,400 shares in the last quarter. Citadel Advisors LLC raised its stake in Chimerix by 131.8% in the third quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock valued at $869,000 after purchasing an additional 94,108 shares in the last quarter. State Street Corp raised its stake in Chimerix by 7.3% in the second quarter. State Street Corp now owns 828,936 shares of the biopharmaceutical company’s stock valued at $4,515,000 after purchasing an additional 56,600 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Chimerix by 38.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,448,250 shares of the biopharmaceutical company’s stock valued at $7,893,000 after purchasing an additional 404,914 shares in the last quarter. Finally, Granite Investment Partners LLC raised its stake in Chimerix by 36.6% in the third quarter. Granite Investment Partners LLC now owns 108,947 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 29,194 shares in the last quarter. 70.32% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/19/1849537.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.